Injectsense

Injectsense develops ultra-miniature, autonomous, continuous, wireless, and rechargeable implantable sensors for digital health applications. The company's smart sensor platform is a customizable, self-anchoring system designed to continuously measure multiple parameters inside the body including absolute pressure, oxygenation, and motion. Its wafer-scale packaging ensures high yields and scalability to millions of devices, leveraging semiconductor supply chain reliability. Injectsense has completed its first human implantation of an ultraminiaturized intraocular pressure sensor for glaucoma treatment, combining years of Silicon Valley engineering expertise in ultra-low power chip design, telemetry, and miniaturization with medical systems development and clinical regulatory expertise. Founded in 2014, headquartered in Emeryville, United States, The company has raised $16.4M at the Series A stage, backed by investors including National Eye Institute, HHS..